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Twenty-First Century Vaccinomics Innovation Systems:
Capacity Building in the Global South and the Role
of Product Development Partnerships (PDPs)
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Abstract
The availability of sequence information from publicly available complete genomes and data intensive sciences,
together with next-generation sequencing technologies offer substantial promise for innovation in vaccinology
and global public health in the beginning of the 21st century. This article presents an innovation analysis for the
nascent field of vaccinomics by describing one of the major challenges in this endeavor: the need for capacities in
‘‘vaccinomics innovation systems’’ to support the developing countries involved in the creation and testing of
new vaccines. In particular, we discuss the need for understanding how institutional frameworks can enhance
capacities as intrinsic to a systems approach to health technology development. We focus our attention on the
global South, meaning the technically less advanced and developing nations in Africa, Asia, and Latin America.
This focus is timely and appropriate because the challenge for innovation in postgenomics medicine is markedly
much greater in these regions where basic infrastructures are often underresourced and new or the anticipated
institutional relationships can be fragile. Importantly, we examine the role of Product Development Partnerships
(PDPs) as a 21st century organizational innovation that contributes to strengthening fragile institutions and
capacity building. For vaccinomics innovation systems to stand the test of time in a context of global public
health, local communities, knowledge, and cultures need to be collectively taken into account at all stages in
programs for vaccinomics-guided vaccine development and delivery in the global South where the public health
needs for rational vaccine development are urgent.
Vaccinomics Innovation Systems
and Postgenomics Medicine
Vaccines are one of the most cost effective public healthtools for tackling priority disease areas in developing
countries (GAVI, 2010). The availability of sequence infor-
mation from publicly available complete genomes (Altenhoff
et al., 2011) and data-intensive sciences (Hey et al., 2009;
Kolker, 2011), together with efforts to characterize the mi-
crobial world using next-generation sequencing technologies
in the postgenomics era (Gilbert et al., 2010) offer substantial
promise for innovation in vaccinology and global health in the
beginning of the 21st century (Hotez and Pecoul, 2010; Ken-
nedy and Poland, 2010). One particular envisioned advance is
rational and mechanistically informed design of vaccines and
directed use (e.g., customized at a subpopulation level) of
vaccine-based public health interventions (Bagnoli and Rap-
puoli, 2006). Indeed, successful application of genomic tech-
nologies was first demonstrated in the innovation of a vaccine
for Neisseria meningitidis serogroup B, reported in 2000 (Pizza
et al., 2000). Since then, reverse vaccinology and other tech-
niques associatedwith antigen identification and the ability to
rapidly and cost effectively sequence genomes, have resulted
in a vastly greater number of potential vaccine candidates
than have been identified over the past 40 years. The analysis
of entire sets of proteins expressed by a genome (the nascent
field of proteomics) is likewise proving to be an important tool
in antigen discovery and in understanding the role of the
environment in regulating the pathophysiology of micro-
organisms (Scarselli et al., 2005; Serruto and Rappuoli, 2006).
With the recent call made in September 2010 for the Human
Proteome Project, we might anticipate further acceleration of
the field of vaccinomics, the convergence of classical vacci-
nology with data intensive sciences and omics technologies.
Notably, this 21st century vaccine innovation system that
utilizes genomics and proteomics in the discovery, develop-
ment, and delivery of new vaccines, is comprised of an in-
creasing number of actors and disciplinary fields. A complex
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and highly diverse set of actors including bioinformatics
specialists, vaccinologists, immunologists, donor agencies,
public health workers, clinical trial sites, government agen-
cies, pharmaceutical industry, civil society, and many more,
are all integral to the vaccinomics innovation process. Each of
these actors requires basic infrastructural capacity to con-
tribute to the innovation system. For example, university re-
searchers require lab space, public health workers need
transport, and government agencies depend on information
and communication technology support.
This article presents an innovation analysis for the nascent
field of vaccinomics by describing one of the major and
hitherto neglected challenges in this endeavor: the need for
capacities in ‘‘vaccinomics innovation systems’’ to support the
developing countries involved in the creation and testing of
new vaccines for global public health. In particular, we dis-
cuss the need for understanding how institutional frame-
works can support minimum capacities as intrinsic to a
systems approach to technology development. Institutions
link the actors in an innovation system and facilitate knowl-
edge production and communication between them. An in-
tegrated innovation system with enhanced capabilities for
communication between actors is essential and timely to the
field of vaccinomics where increased multidisciplinarity also
demands more effective knowledge translation, communica-
tion, and diffusion.
We focus our attention on the global South, meaning the
technically less advanced and developing nations in Africa,
Asia, and Latin America. This focus is timely and appropriate
because the challenge for innovation is markedly much
greater in these regions where basic infrastructures are often
underresourced and new or the anticipated institutional re-
lationships can be fragile. Importantly, we examine the role of
Product Development Partnerships (PDPs)—a concept that has
attracted considerable interest in the field of global health—as
an institutional innovation that contributes to strengthening
fragile institutions and capacity building. Alongside the po-
tential that PDPs offer for the 21st century vaccinomics in-
novation systems, there are important challenges that should
be considered as well.
Building Global Health Capacities and PDPs
for 21st Century Vaccine Innovation
Innovation systems for global health care, medicines, and
devices have evolved significantly to take account of the
global value and supply chains as well as an increased
number of actors with a greater range and global spread of
knowledge and expertise. Our understanding of innovation
has moved from a linear model of knowledge production
where innovation primarily occurs in academic and private
laboratory settings, moving through a linear pipeline of
product development, to more complex systems models.
Importantly, the systems approach to innovation (Lundvall,
1992) recognizes processes of interactive learning and
knowledge translation between actors. This complex and
often tacit process of knowledge exchange and translation
requires a sustainable and strong institutional framework to
facilitate interaction (Freeman, 1987; Metcalf, 1995).
Adequate institutional frameworks contribute to the over-
all capacity for vaccine innovation in developing countries.
This is no less applicable to the field of vaccinomics. In the
context of vaccine innovation, capacity is the ability to per-
form functions, solve problems, and set and achieve techno-
logical objectives (Fukuda-Parr et al., 2002). Two elements are
central to capacity building: adequate expertise and func-
tional institutions. In the context of developing countries, the
former is rarely adequate and relies on the funding and
training provided by international development/health or-
ganizations. The latter tends be undermined and weakened
by national structural problems, that is, aid dependency, un-
stable democracies, and lack of functional and responsive
institutions (e.g., national regulatory authorities, local plat-
forms for community engagement).
A core problem in developing countries is missing institu-
tions or perverse institutions (Burnside and Dollar, 1997;
North, 1990) that undermine the effectiveness of an innova-
tion system, for example, those that lead to misinformation or
the unintended diversion of resources. This is worsened by
high turnover of personnel, weak institutional structures, and
lack of transparency. In some cases, these institutional inad-
equacies have been addressed with the support of interna-
tional organizations (e.g., World Bank, WHO, UN) by
providing technical assistance (Wilson, 2007). Weak institu-
tions and failure in knowledge communication can persist,
however, because international aid programs often use a lin-
ear top-down approach (Brett, 2000) to institution building
rather than a bottom-up approach that engages with local
knowledge bases. Weak institutions and resulting insufficient
capacities that fail to facilitate knowledge transfer and en-
gagement between actors, including those at the community
and policy level, can endanger a whole health program and
health systems. Consequences range from insufficient enroll-
ment of communities in clinical trials and low levels of uptake
of the final vaccine product, to poor rates of success where
disease control requires multiple interventions and strategies
(e.g., malaria) (Keusch et al., 2010).
Public Private Partnerships (PPP) and more recently, a
specific variant, PDPs, have emerged as new institutional in-
novations that have the potential to build capacities for vac-
cine innovation in developing countries. PDPs have arisen as
solutions where the costs and risks associated with research
act as barriers to product development. PDPs create long-term
partnerships and build trust between specific actors (usually
academia, industry, the public sector, and international
agencies), toward the achievement of a common technological
goal. They work as virtual nonprofit R&D organizations,
outsourcing research activities to academic or private sector
partners, while linking together expertise and providing
public funding, technical oversight, and portfolio manage-
ment. PDPs can leverage additional funds and negotiate
terms with partners with regard to prices, preferential access
and other aspects of benefit sharing. They usually focus on a
specific technology (e.g., vaccines, drugs, or diagnostics) and
work within a particular disease area. Recent research evi-
dence from 122 health technology candidates in the combined
PDP pipeline include 90 biopharmaceutical candidates and 32
diagnostic and vector control candidates (Grace, 2010). The
International AIDS Vaccine Initiative (IAVI), for example, is a
PDP that has attracted large amounts of donor funding. It
aims to increase scientific and technological related capacities
in the South, and institutional capacity through local owner-
ship of vaccine development resulting from advocacy initia-
tives (Chataway and Hanlin, 2008). Table 1 lists other
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examples of PDPs that are involved in vaccine development.
At a higher organizational resolution, the Figure 1 schemati-
cally maps out many of the partners involved in the IAVI PDP
and their attendant roles.
In the case of South Africa, PDPs such as IAVI and the
South African AIDS Vaccine Initiative (SAAVI), have de-
monstrated both the potential for, and challenges to this new
approach to health innovation. Qualitative data from two
clinical trial sites (Upton, 2011) reveal socioeconomic, cultural,
political, and institutional constraints on effective mecha-
nisms for knowledge communication between the researchers
and the communities involved. The capacity of community
members to absorb HIV/AIDS and vaccine science know-
ledge is crucial to the ethical and effective conduct of clinical
trials. Equally important is the capacity of trial site researchers
to understand the social and cultural factors that confound
aims to achieve as wide a representation and retention of trial
participants as possible across diverse populations over long
periods of time. Moreover, in the case of HIV prevention
clinical trials in developing country settings, the ‘‘law on the
streets’’ may be quite different than the ‘‘law in the books’’
(Burris and Davis, 2009). Such functional disconnects in civil
liberties of citizens may result in multiple, dynamic, and in-
tersecting risk factors that warrant anticipatory governance
and real-time monitoring of the social risks for clinical trial
participants (Ozdemir, 2009).
Insecurity underpins immediate priorities of food and
employment in such contexts. Even so, given the high pre-
valence of HIV/AIDS in South Africa (UNAIDS, 2010), com-
munity members’ motivation for involvement in community
engagement activities and community interest in health in-
novation are evident. Challenges arise, however, from the
high turnover of those involved causing ‘‘information decay’’
(Lesch et al., 2006). The problem in recruiting trial participants
frommarginalized and vulnerable populations is due, in part,
to health beliefs and HIV/AIDS stigma. Ambivalence toward
a positivist and scientific approach to HIV/AIDS and fears of
association with the ‘‘white coats’’ from trial site clinics have
cultural and historical roots. For example, the knowledge of
past damaging medical interventions, such as the Tuskegee
syphilis experiment (Marshall, 2005), and the legacy of racism
under apartheid reinforced suspicions that clinical scientists
were injecting black trial participants with the HIV virus
(Upton, 2011). In addition government reticence in accepting
responsibility for the wide range of factors contributing to the
spread and treatment of HIV/AIDS (Nattrass, 2007) has
contributed to such ambivalence. At the institutional level,
conflicting accountabilities to donors and communities, due
to priorities in developing science and technology capacity,
threaten ethical and effective community engagement in the
clinical trial process (Upton, 2011).
It has been recognized that building capacities at the na-
tional level for scientific diplomacy is important for know-
ledge exchange in an innovation system that involves global
players and is working toward various vaccine solutions in
the global South (Singer and Daar, 2001). We suggest, how-
ever, that the potential for developing PDP capacities also lies




To develop a low-cost vaccine for meningitis
PATH-VAC To develop vaccines for Enteric Vaccine Initiative, Advancing Rotavirus Vaccine,
Pneumococcal Vaccine Project, and Influenza Vaccine Project.
International Vaccine
Institute
International center of research, training, and technical assistance for vaccines needed
in developing countries (e.g., new oral cholera vaccine, Shanchol). Located in Korea
Path Malaria Vaccine
initiative
To accelerate malaria vaccine development.
Pediatric Dengue
Vaccine Initiative
To accelerate the development, evaluation, and sustained use of affordable dengue
vaccines
IAVI To ensure the development of safe, effective, accessible, preventive HIV vaccines
Medicines for Malaria
Venture
To discover, develop, and deliver new, affordable antimalarial drugs
Institute for One
World Health
R&D to combat infectious diseases in developing countries (e.g., Visceral
leishmaniasis, Malaria, and Diarrheal disease)
Aeras To develop new tuberculosis vaccines
The TB Alliance To accelerate the discovery and development of new TB drugs
FIG 1. Collaborations within the International AIDS Vac-
cine Initiative (IAVI) PDP.
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in supporting communities in challenging negative social
norms around target diseases such as HIV/AIDS and pro-
viding adequate funding for trial site resources (Upton,
2011). Communities can provide knowledge about their
own histories and cultures, which can be usefully employed in
strengthening the efforts of PDPs to build capacity. Oppor-
tunities to exchange that knowledge via national and global
networks further promote learning and reflexive behavior
and increase the potential for ‘‘shared health governance’’
(Ruger, 2010), which can also underpin a successful approach
to PDP involvement in health innovation.
Conclusions and Forward Look
It is interesting to note that the fields of global health and
global health governance have reached a critical juncture over
the past few years (Kickbusch et al., 2010; Ozdemir et al. 2009;
Pang et al., 2010). This is not only due to their visibility and the
complexity of the challenges they pose. Presently, a chaotic set
of actors and networks struggle to work toward improve-
ments in global health while they remain very poorly coor-
dinated. It is against this highly dynamic and complex
background that the new field of vaccinomics is rapidly
emerging. Vaccines and the field of vaccinomics represent a
complex evolving 21st century data-intensive innovation that
integrates the recent developments in genomics and pro-
teomics with classical vaccinology in the postgenomics era.
Current systems for the innovation and development of vac-
cines take place in a global context that demands collaboration
among a wide variety of actors such as international agencies,
national government agencies, communities, and the private
sector. It is important to bear in mind that adequate capacities
for vaccine innovation do not equate to the linear sum of these
individuals, organizations, or their resources or expertise.
Capacities crucially rely on the interaction of and exchange of
expertise and knowledge in an institutional context that pro-
motes learning and reflexive behavior. The latter relates to the
ability of scientists (or other stakeholders in an innovation
system) to be cognizant of how their own values and as-
sumptions may contribute to, and influence the creation of
meaning(s) from their own research. This is important as
throughout the past century, science has been framed as if it is
a value-free autonomous activity that is not affected by social
systems or human values more generally. For sustainable 21st
century vaccinomics innovation systems, we need to bear in
mind that knowledge is coproduced by both science and so-
cial systems in which it is embedded ( Jasanoff, 2006). To this
end, PDPs are a social institutional innovation that can provide
more formal and transparent structures on which to build
long-term sustainable partnerships and trust, to reinforce or
substitute for the often weak institutional frameworks that
exist in developing countries.
The cases of IAVI and SAAVI in South Africa attest to the
challenges that still prevail, despite the institutional frame-
works advanced by PDPs (Upton, 2011). Social and cultural
factors are at the core of capabilities and the successful es-
tablishment of institutions between actors in an innovation
system. For vaccinomics innovation systems to stand the test
of time in a context of global public health, local communities,
knowledge and cultures need to be collectively taken into
account at all stages in programs for vaccinomics-guided
vaccine development and delivery in the global South where
the public health needs for rational vaccine development are
urgent.
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